🔎 Trials Near Me

Beranda › Kanker Esofagus › Massachusetts › Boston

Uji klinis Kanker Esofagus di Boston, MA

23 studi untuk Kanker Esofagus mencari peserta di lokasi sekitar Boston (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Menerima pesertaFase 1
  • Massachusetts General Hospital, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06465069

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Menerima pesertaFase 2
  • Dana-Farber Cancer Institute - Oncology Department, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06760819

Distance-Based Exercise to Preserve Function and Prevent Disability

Menerima peserta
  • Dana-Farber Cancer Institute, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07059884

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Menerima pesertaFase 1
  • Brigham and Women's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07090499

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

Menerima pesertaFase 1
  • Massachusetts General Hospital, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07578571

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Menerima pesertaFase 1/2
  • Tufts Medical Center, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06047379

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

Menerima pesertaFase 2
  • Massachusetts General Hospital (Data Collection Only), Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06123338

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Menerima pesertaFase 1
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07114601

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Menerima pesertaFase 1
  • Massachusetts General Hospital, Boston
  • Beth Israel Deaconess Medical Center, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07213791

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Menerima pesertaFase 1/2
  • Dana Farber Cancer Institute, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06128551

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Menerima pesertaFase 1
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT05983432

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.

Menerima pesertaFase 3
  • Massachusetts General Hospital, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07217704

Resilience and Equity in Aging, Cancer, and Health (REACH)

Menerima peserta
  • Dana-Farber Cancer Institute, Boston
Usia 65 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT04674267

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Menerima pesertaFase 1
  • Dana Farber Cancer Institute, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT06293898

Serial MRI Scans During Radiation Therapy

Menerima peserta
  • Brigham and Women Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT04188535

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

Menerima pesertaFase 2
  • Massachusetts General Hospital, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT07070466

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

Menerima pesertaFase 1
  • Mass General Cancer Center, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Agu 2026 · NCT07227168

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Menerima pesertaFase 1/2
  • Massachusetts General Hospital Cancer Center, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT05592626

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Menerima pesertaFase 1/2
  • Massachusetts General Hospital - Dana Farber, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Jul 2026 · NCT03526835

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Menerima pesertaFase 1
  • Massachusetts General Hospital, Boston
  • Brigham & Women's Hospital, Boston
  • Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
  • dan 2 lainnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT04389632

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Menerima pesertaFase 1/2
  • Massachusetts General Hospital, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT06239194

Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers

Menerima pesertaFase 1/2
  • Massachusetts General Hospital, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Jan 2026 · NCT02584244

Uji klinis Kanker Esofagus di kota lain

Studi lain di Boston

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.